text.skipToContent text.skipToNavigation
No results found
Search Suggestions

CAR-T Cells: Breakthroughs in Cancer and Auto-Immune Therapies

One of the most revolutionary cell therapies to transition from bench to bedside in the past decade is undoubtedly the development of chimeric antigen receptor (CAR)-T cells. Here, CAR-T cells have found a plethora of different applications. Firstly, by proving to be an effective treatment for certain blood cancers that were previously deemed incurable. Secondly, in holding promise for treating certain auto-immune diseases and solid tumours.

Read more

Read less

CAR-T Cell Development – The Future of Fighting Cancer


CAR-T cells, genetically engineered and equipped with specific receptors to target and combat cancer cells, are primarily divided into two categories: autologous and allogenic CAR-T cells. Hereby, autologous CAR-T cells derive from the patient’s own white blood cells and are reintroduced after modification, whereas allogenic CAR-T cells are designed as off-the-shelf solutions for use in different patients. However, both approaches have their challenges. The manufacturing process for autologous CAR-T cells is complex and costly, as each patient’s cells must be individually processed. Allogeneic CAR-T cells, on the other hand, currently do not have the same safety profile, necessitating further research to address these issues.